For early diagnosis of MI and monitoring of ACS

The Cardiac Array combines routine with novel early markers to give a clear picture of a patient’s cardiac status. It can be used in A&E settings as well as cardiac and medical wards to determine the diagnosis of MI, and assess the patient’s risk of future cardiac events.

A 3 year study with over 1000 patients confirmed the cardiac biochip to be 89% sensitive for MI diagnosis shortly after a cardiac event (3-6 hours), which constitutes a 20% increase in sensitivity against troponin alone. It also has the ability of ACS profiling and, with a negative predictive value of 98% at 3-6 hours, is a perfect rule out test for the emergency setting.

• Results available from 20 minutes
• Near-patient and central laboratory analysers available
• 98% rule out test for MI within 3-6 hours post pain onset
• Improved risk stratification of patients with suspected ACS

Cardiac Array

• Heart-type fatty acid binding protein (h-FABP)
• Myoglobin (MYO)
• Troponin I (cTnI)
• Creatine-Kinase Muscle Brain (CK-MB)

Cardiac Plus Array

• Designed specifically for research applications:
• h-FABP
• MYO
• CTnI
• CK-MB
• CA III
• GP-BB

A full range of controls and calibrators are also available.